Parkinson's disease managing reversible neurodegeneration [Corrigendum]

Código QR

Parkinson's disease managing reversible neurodegeneration [Corrigendum]

Hinz M, Stein A, Cole T, McDougall B, Westaway M. Neuropsychiatric Disease and Treatment. 2016;12:763–775.On page 774, Disclosure section, “MH discloses his relationship with DBS Laboratory services and NeuroResearch Clinics, Inc. The other authors report no conflicts of interest...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hinz M, Stein A, Cole T, McDougall B, Westaway M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/efa130d8f10e493b89976379d6f63e5f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Parkinson’s disease managing reversible neurodegeneration
por: Hinz M, et al.
Publicado: (2016)

Parkinson’s Disease Managing Reversible Neurodegeneration [Retraction]
por: Hinz M, et al.
Publicado: (2020)

Parkinson’s Disease Managing Reversible Neurodegeneration [Expression of Concern]
por: Hinz M, et al.
Publicado: (2020)

Parkinson’s disease-associated melanin steal
por: Hinz M, et al.
Publicado: (2014)

Review: management of Parkinson&#39;s disease
por: Pedrosa DJ, et al.
Publicado: (2013)

Astrogliosis and sexually dimorphic neurodegeneration and microgliosis in the olfactory bulb in Parkinson’s disease
por: Alicia Flores-Cuadrado, et al.
Publicado: (2021)

Parkinson’s Disease-Associated Melanin Steal [Retraction]
por: Hinz M, et al.
Publicado: (2021)

Parkinson’s Disease-Associated Melanin Steal [Expression of Concern]
por: Hinz M, et al.
Publicado: (2020)

Adjunctive therapy in Parkinson&#39;s disease: the role of rasagiline
por: Gaines KD, et al.
Publicado: (2012)

The effect of cognitive status and visuospatial performance on affective theory of mind in Parkinson's disease
por: McKinlay A, et al.
Publicado: (2013)

The impact of nonmotor symptoms on quality of life in patients with Parkinson's disease in Taiwan
por: Liu WM, et al.
Publicado: (2015)

A case of early onset Parkinson's disease after major stress
por: Zou K, et al.
Publicado: (2013)

Do neurologists in Germany adhere to the national Parkinson&#39;s disease guideline?
por: Sabrina Schr&ouml;der, et al.
Publicado: (2011)

Parkinson’s disease patient-specific neuronal networks carrying the LRRK2 G2019S mutation unveil early functional alterations that predate neurodegeneration
por: G. Carola, et al.
Publicado: (2021)

Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders
por: Cera N, et al.
Publicado: (2014)

Neuroprotective strategies against calpain-mediated neurodegeneration
por: Yildiz-Unal A, et al.
Publicado: (2015)

Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson's disease with dementia: data from the Swedish Dementia Quality Registry (SveDem)
por: Fereshtehnejad SM, et al.
Publicado: (2013)

Protection from α-Synuclein induced dopaminergic neurodegeneration by overexpression of the mitochondrial import receptor TOM20
por: Briana R. De Miranda, et al.
Publicado: (2020)

5-HTP efficacy and contraindications
por: Hinz M, et al.
Publicado: (2012)

APRESS: apical regulatory super system, serotonin, and dopamine interaction
por: Hinz M, et al.
Publicado: (2011)

Editor&#39;s choice
por: Pinder RM
Publicado: (2012)

Phosphorylation of Tau and α-Synuclein Induced Neurodegeneration in MPTP Mouse Model of Parkinson’s Disease
por: Hu S, et al.
Publicado: (2020)

Timing variability and midfrontal ~4 Hz rhythms correlate with cognition in Parkinson’s disease
por: Arun Singh, et al.
Publicado: (2021)

Heterogeneity of prodromal Parkinson symptoms in siblings of Parkinson disease patients
por: Luca Baldelli, et al.
Publicado: (2021)

Corrigendum
por: Sailasuta N, et al.
Publicado: (2011)

Integrated molecular landscape of Parkinson’s disease
por: C. J. H. M. Klemann, et al.
Publicado: (2017)

The Gordon Research Seminar & Conference on Parkinson’s disease: state of the Science 200 years after James Parkinson’s essay on the Shaking Palsy
por: J. T. Greenamyre, et al.
Publicado: (2017)

A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole
por: Marty Hinz, et al.
Publicado: (2010)

The dual-gate lumen model of renal monoamine transport
por: Marty Hinz, et al.
Publicado: (2010)

Imaging tau pathology in Parkinsonisms
por: Sarah Coakeley, et al.
Publicado: (2017)

Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson’s disease
por: Per Odin, et al.
Publicado: (2018)

Case-control study of hypertension and Parkinson’s disease
por: Yuen-Fann Ng, et al.
Publicado: (2021)

Embryonic development of selectively vulnerable neurons in Parkinson’s disease
por: Miguel A. P. Oliveira, et al.
Publicado: (2017)

Delayed orthostatic hypotension in Parkinson’s disease
por: Sang-Won Yoo, et al.
Publicado: (2021)

Imaging Parkinson’s disease below the neck
por: Per Borghammer, et al.
Publicado: (2017)

Multimodal phenotypic axes of Parkinson’s disease
por: Ross D. Markello, et al.
Publicado: (2021)

Alzheimer's disease and its treatment costs: case study in the Czech Republic
por: Mohelska H, et al.
Publicado: (2015)

LRRK2 levels in immune cells are increased in Parkinson’s disease
por: D. A. Cook, et al.
Publicado: (2017)

Association between Parkinson’s disease and the faecal eukaryotic microbiota
por: Severin Weis, et al.
Publicado: (2021)

Prevalence of Parkinson’s disease and other types of Parkinsonism in Al Kharga district, Egypt
por: El-Tallawy HN, et al.
Publicado: (2013)